Hologic
HOLX
#1060
Rank
$18.12 B
Marketcap
$78.04
Share price
-0.67%
Change (1 day)
8.54%
Change (1 year)
Categories
Hologic, Inc. is an American medical technology company primarily focused on womenโ€™s health, the company sells medical devices for diagnostics, surgery, and medical imaging.

P/E ratio for Hologic (HOLX)

P/E ratio as of November 2024 (TTM): 40.0

According to Hologic's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 40.0205. At the end of 2022 the company had a P/E ratio of 18.9.

P/E ratio history for Hologic from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202218.965.99%
202111.4-16.5%
202013.7-75.66%
201956.1-304.89%
2018-27.4-347.4%
201711.1-67.15%
201633.7-42.49%
201558.6-60.54%
2014149-3017.94%
2013-5.09-91.35%
2012-58.9-315.11%
201127.4-143.61%
2010-62.73659.67%
2009-1.67-100.38%
2008436-1274.22%
2007-37.1-160.43%
200661.410.11%
200555.856.31%
200435.7-46.23%
200366.3-83.7%
2002407-4481.05%
2001-9.29

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
33.4-16.46%๐Ÿ‡บ๐Ÿ‡ธ USA
40.1 0.12%๐Ÿ‡บ๐Ÿ‡ธ USA
110 174.77%๐Ÿ‡บ๐Ÿ‡ธ USA
39.0-2.54%๐Ÿ‡บ๐Ÿ‡ธ USA
20.8-47.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-36.9-192.16%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
23.9-40.37%๐Ÿ‡บ๐Ÿ‡ธ USA
10.9-72.84%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.